Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (June 2015)

30 slides from Sorrento Therapeutics's investor presentation, June 2015

  1. Slide 1: Next-Generation Cancer Therapeutics

    Slide 1: Next-Generation Cancer Therapeutics

    Next-Generation Cancer Therapeutics June 2015 1

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements NASDAQ: SRNE Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward-looking

  3. Slide 3: A Comprehensive Approach to Cancer Treatment

    Slide 3: A Comprehensive Approach to Cancer Treatment

    A Comprehensive Approach to Cancer Treatment Deep and complementary pipeline creates significant opportunities for novel, breakthrough mono-or combination therapies against cancer. 3

  4. Slide 4: Recent Corporate Events

    Slide 4: Recent Corporate Events

    Recent Corporate Events T26 THERAPCUTCS Off-the-shelf CAR-TNK (Chimeric Antigen Receptor Tumor-attacking Neukoplast®) Sorrento wholly-owned subsidiary Leader in cellular immunotherapy conkwest Exclusive global collaboration to develop next generation ‘off-the-shelf’ CAR.TNK immunotherapies for cance

  5. Slide 5: Sorrento Pipeline Overview

    Slide 5: Sorrento Pipeline Overview

    Sorrento Pipeline Overview PDL1.TNK, CD123.TNK, ROR1.TNK, PSMA.TNK, CAR.TNK and G-MAB are trademarks owned by Sorrento Therapeutics, Inc. 5

  6. Slide 6: Immunotherapy Program G-MAB

    Slide 6: Immunotherapy Program G-MAB

    Immunotherapy Program G-MAB + Neukoplast + Proprietary Toxins & Conjugation Chemistries Bispecific Abs 6

  7. Slide 7: Sorrento's G-MAB Antibody Library

    Slide 7: Sorrento's G-MAB Antibody Library

    Sorrento’s G-MAB Antibody Library 7

  8. Slide 8: Wholly-owned subsidiary of Sorrento Therapeutics

    Slide 8: Wholly-owned subsidiary of Sorrento Therapeutics

    Wholly-owned subsidiary of Sorrento Therapeutics 8 CAR.TNK and TNK Therapeutics are trademarks owned by Sorrento Therapeutics, Inc.

  9. Slide 9: The Next Generation of the Next Generation

    Slide 9: The Next Generation of the Next Generation

    “The Next Generation of the Next Generation” Neukoplast G-MAB Library NK92 cell line (“off-the-shelf”) Vast diversity human antibody library Broad anti-cancer activity in solid and liquid High successful screening rate (over 70 targets screened) tumors Proprietary technologies with FTO No clinical D

  10. Slide 10: Background of NK92 (Neukoplast; aNK)

    Slide 10: Background of NK92 (Neukoplast; aNK)

    Background of NK92 (Neukoplast™; aNK) Amplified serial killing Pure NK Line Single source Master Cell Bank Large tank reactor Bioengineerable Missing 'off-switch' No T-cell contamination Batch-to-batch consistency Cryopreservation / Pipeline Enhanced targeting Broad anti-cancer activity No Graft vs.

  11. Slide 11: NK92 is Hypo-Immunogenic and Highly Potent

    Slide 11: NK92 is Hypo-Immunogenic and Highly Potent

    NK92 is Hypo-Immunogenic and Highly Potent High Granzyme MLR Assay Production Mixed Lymphocyte Reaction (MLR) assay: NK92 do not in NK92 stimulate allogeneic T cells Lymphocytes from 2 healthy donors co- cultured with each other → vigorous proliferation Co-cultured with NK92 (7 days) → no proliferat

  12. Slide 12: Unmodified NK92 Clinically Validated: Phase I

    Slide 12: Unmodified NK92 Clinically Validated: Phase I

    Unmodified NK92 Clinically Validated: Phase I Advanced metastatic disease refractory to chemo, biologics, cytokines, radiation, and surgery Nearly half the patients received multiple dosing regimens (up to 6 months) Promising activity against different cancer types, including acute myelogenous leuke

  13. Slide 13: Phase I Studies: Summary of Findings

    Slide 13: Phase I Studies: Summary of Findings

    Phase I Studies: Summary of Findings Excellent Safety Demonstrated No adverse T-cell induced cytotoxic response A significant safety concern for CAR-T cell approaches No pre-conditioning or combination treatment Notable responses: Melanoma: 1/1 Lung Cancer: 3/4 (1 MR, 2 PR) Renal Cell Cancer: 6/11 (

  14. Slide 14: TNK: CAR-Modified NK92

    Slide 14: TNK: CAR-Modified NK92

    TNK: CAR-Modified NK92 Clonal cell lines expressing one or more CARs to establish a range of distinct products Multiple killing mechanisms - CAR-targeted as well as broad intrinsic anti- cancer activity of NK92 (“off-target / on-tumor”) Engages the adaptive immune system through cytokine secretion a

  15. Slide 15: HER2.TNK

    Slide 15: HER2.TNK

    HER2.TNK In-Vivo Preclinical Mouse Data Homing to HER2-expressing tumors Inhibition of HER2+ RCC metastasis “Serial killing” of HER2-positive target cells even after gamma radiation with Schönfeld et al., Mol Ther. 23(2):330-8, 2015 10 Gy Selective cytotoxicity (spares normal cells) 15

  16. Slide 16: Tumor Homing and Potent Anti-Glioma Activity in Mice

    Slide 16: Tumor Homing and Potent Anti-Glioma Activity in Mice

    Tumor Homing and Potent Anti-Glioma Activity in Mice Tumor Homing of TNKs Intracranial LN-319 glioblastoma xenografts in NSG mice NK92 FACS Analysis NK92 Her2.TNK NK92 Her2.TNK 16

  17. Slide 17: TNK vs. CAR-T Cells: Key Differentiators

    Slide 17: TNK vs. CAR-T Cells: Key Differentiators

    TNK vs. CAR-T Cells: Key Differentiators CAR.TNK CAR-T Cells Cell Production Off-the-shelf universal product; Autologous (patient-derived) via leukapheresis; CAR-modified NK92 cells personalized therapy Transduction Master cell bank Viral transfection & variable CAR expression levels (100% of cells

  18. Slide 18: TNKs being generated by Sorrento

    Slide 18: TNKs being generated by Sorrento

    TNKs being generated by Sorrento TNK being generated SORRENTO –CONKWEST COLLABORATION FRAMEWORK: Indications by Sorrento AML CD123.TNK CAR targets selected by Joint Steering Committee. Glioma EGFRviii.TNK CAR.TNKs programs split between both companies. Lead company Glioma EphA3.TNK responsible for a

  19. Slide 19: TNK Development: Next Steps

    Slide 19: TNK Development: Next Steps

    TNK Development: Next Steps H1 2015 Generation of in-house CARs Generation and evaluation of H2 2015 stable TNK pools and cell lines 2016 IND-enabling studies, IND submission, and initiation of Phase I Studies 19

  20. Slide 20: Anti-PD-L1 mAb Exhibits Potent Activity

    Slide 20: Anti-PD-L1 mAb Exhibits Potent Activity

    Anti-PD-L1 mAb Exhibits Potent Activity 20

  21. Slide 21: Anti-PD-L1 mAb Synergistic with HSP90 Inhibitor In Vivo

    Slide 21: Anti-PD-L1 mAb Synergistic with HSP90 Inhibitor In Vivo

    Anti-PD-L1 mAb Synergistic with HSP90 Inhibitor In Vivo C57 BL/6 mice bearing MC38 colon carcinomas (n = 7/group) were treated with 200 μg IgG1 control or the anti-PD-L1 antibody STI-A1015 (dosed on day 8, 12 ,and 15), either alone or in combination with 125 mg/kg ganetespib (Synta Pharmaceuticals C

  22. Slide 22: In Vivo Proof-of-Concept of Sorrento ADCs

    Slide 22: In Vivo Proof-of-Concept of Sorrento ADCs

    In Vivo Proof-of-Concept of Sorrento ADCs VEGFR2-ADC STI-D0168 c-MET-ADC STI-D0602 A431 squamous-cell carcinoma cells; maytansinoid drug conjugates 22 ^indicates dosing U87 xenograft; dosing twice weekly; maytansinoid drug conjugates

  23. Slide 23: Resiniferatoxin (RTX): A Novel, Non-opiate Analgesic

    Slide 23: Resiniferatoxin (RTX): A Novel, Non-opiate Analgesic

    Resiniferatoxin (RTX): A Novel, Non-opiate Analgesic Intractable RTX Cancer Pain 23

  24. Slide 24: RTX Target Product Profile

    Slide 24: RTX Target Product Profile

    RTX Target Product Profile MOA: Ultrapotent, highly specific TRPV1 agonist selectively targeting afferent neurons Efficacy: Meaningful analgesia with concomitant opioid reduction and improvement in function Safety: Alteration of heat sensation in the targeted area with effect on normal perception /

  25. Slide 25: Two Injection Sites = Two Products for Human Use

    Slide 25: Two Injection Sites = Two Products for Human Use

    Two Injection Sites = Two Products for Human Use Epidural injection into or Spinal Cord Cross Section near the dorsal root ganglion (DRG) for unilateral or diffuse pain Intrathecal injection into the cerebrospinal fluid space (CSF) targeting both DRGs and dorsal horn neurons 25

  26. Slide 26: NIH/NINDS Summary Data Overall

    Slide 26: NIH/NINDS Summary Data Overall

    NIH/NINDS Summary Data Overall 12 advanced cancer patients with severe refractory pain have received a single IT RTX injection 15thWorld Congress on Pain (IASP), October 6 –11, 2014, Buenos Aires, Argentina, Poster # PF025: Intrathecal Administration of Resiniferatoxin for Treating Intractable Cance

  27. Slide 27: 2 Patients from New Cohort (2015)

    Slide 27: 2 Patients from New Cohort (2015)

    2 Patients from New Cohort (2015) Colorectal Cancer: Stage IV Lung and Rectal Cancer 43 year old female with severe 60 year old male with severe bilateral lower abdominal and rectal pain pelvic and sacral pain Post RTX Post RTX • No pain day after RTX, by day 28 • Substantial pain reduction from 7-1

  28. Slide 28: Next Steps for RTX Development

    Slide 28: Next Steps for RTX Development

    Next Steps for RTX Development 2015 Complete NIH dose ranging IT safety study (cancer pain) Start NIH POC EpiPG study (cancer-induced bone pain [CIBP]) Complete tox package to support corporate IND for IT RTX Begin tox package to support corporate IND for EpiPG RTX (upper thoracic and lumbar approac

  29. Slide 29: A Comprehensive Approach to Cancer Treatment

    Slide 29: A Comprehensive Approach to Cancer Treatment

    A Comprehensive Approach to Cancer Treatment Deep and complementary pipeline creates significant opportunities for novel, breakthrough mono-or combination therapies against cancer. 29

  30. Slide 30: Next-Generation Cancer Therapeutics

    Slide 30: Next-Generation Cancer Therapeutics

    Next-Generation Cancer Therapeutics CONTACT: George Uy Henry Ji, Ph.D. Executive Vice President and CCO President and CEO [email protected] [email protected] (661) 607-4057 (858) 668-6923 30

Source: company website

More decks from Sorrento Therapeutics, Inc.

All 41 Sorrento Therapeutics decks